```html

Eosinophilic Fasciitis: A Comprehensive Medical Guide

Overview

Eosinophilic fasciitis (EF), also known as Shulman syndrome, is a rare inflammatory connective‑tissue disease that primarily affects the fascia—the thick band of tissue surrounding muscles, blood vessels, and nerves. The condition leads to painful swelling, tightening, and hardening (fibrosis) of the skin and subcutaneous tissues, most often in the arms and legs.

Who it affects: EF can occur at any age but most commonly presents in adults between 40 and 60 years old. Women are slightly more affected than men (approximately 1.5 : 1). Cases have been reported worldwide, though the exact prevalence is uncertain because the disease is under‑diagnosed. Current estimates from the United States suggest an incidence of roughly 0.5–1 case per million people per year <sup>1</sup>.

Key points:

• Rapid onset of limb swelling and hardness within weeks to months.
• Unlike systemic sclerosis, EF typically spares the face and hands.
• Elevated eosinophil count in blood and tissues is a hallmark.

Symptoms

The clinical picture may vary, but most patients experience a cluster of the following manifestations:

Skin and Soft‑Tissue Changes

• Swelling (edema) of the distal arms or legs, often symmetric.
• Induration and “peau d’orange” appearance – the skin feels firm, thick, and dimpled, similar to an orange peel.
• Restricted joint range of motion caused by fascial tightening, leading to difficulty raising arms, climbing stairs, or bending wrists.
• Painful “groove” or “groove sign” – a visible depression along the veins where the fascia contracts.

Systemic Symptoms

• Fever or low‑grade chills (present in ~30 % of cases).
• Fatigue and malaise.
• Weight loss (unintentional) in severe disease.

Laboratory and Imaging Findings (not symptoms but often noted by patients)

• Peripheral eosinophilia (elevated eosinophil count > 500 cells/µL).
• Elevated erythrocyte sedimentation rate (ESR) or C‑reactive protein (CRP).
• Hypergammaglobulinemia in ~20 % of cases.

Causes and Risk Factors

The exact cause of EF remains unknown, but several triggers and associations have been identified:

• Physical exertion or trauma – up to 40 % of patients recall a strenuous workout, weight‑lifting, or a minor injury before symptom onset.
• Medications – rare reports link EF to statins, checkpoint inhibitors (e.g., pembrolizumab), and certain antibiotics, suggesting a drug‑induced immune reaction.
• Infections – some cases follow viral (e.g., parvovirus B19) or bacterial infections, though a causal link is not proven.
• Autoimmune background – a minority of patients have concomitant autoimmune diseases such as rheumatoid arthritis, lupus, or thyroiditis, hinting at shared immune dysregulation.

Risk Factors

• Age 40–60 years
• Female sex (slightly higher prevalence)
• Recent intense physical activity or trauma
• Use of certain immunomodulatory drugs
• Family history of autoimmune disorders (although hereditary patterns are not established)

Diagnosis

Diagnosing EF requires a combination of clinical evaluation, laboratory testing, imaging, and—crucially—tissue biopsy.

Step‑by‑step diagnostic approach

1. Clinical Assessment: Detailed history (onset, triggers, systemic symptoms) and physical exam focusing on limb induration, groove sign, and joint restriction.
2. Laboratory Tests:
   • Complete blood count (CBC) with differential – look for eosinophilia.
   • ESR / CRP – markers of inflammation.
   • Serum IgG, ANA, rheumatoid factor – to rule out other connective‑tissue diseases.
3. Imaging:
   • Magnetic Resonance Imaging (MRI) – shows thickened fascia with high T2 signal, useful for guiding biopsy.
   • Ultrasound – can detect fascial thickening and fluid collections, convenient for bedside assessment.
4. Full‑thickness Fascial Biopsy (the gold standard):
   • Sample includes skin, subcutis, and underlying fascia.
   • Histology typically reveals eosinophil‑rich inflammation, collagen deposition, and fibrosis.
5. Exclusion of Mimics:
   • Systemic sclerosis, scleroderma‑like disorders, eosinophilic granulomatosis with polyangiitis, and deep vein thrombosis must be ruled out.

Treatment Options

Early treatment improves outcomes and limits permanent contractures. Therapy is individualized based on disease severity, comorbidities, and response.

First‑Line Medications

• Corticosteroids (e.g., prednisone 0.5–1 mg/kg/day):
  • Rapidly reduces inflammation and eosinophil count.
  • Tapered over 6–12 months to minimize side effects.
• Immunosuppressants added when steroids alone are insufficient or when tapering causes relapse:
  • Methotrexate – 15–25 mg weekly; most commonly used steroid‑sparing agent.
  • Mycophenolate mofetil – 1–2 g/day, especially in patients with liver concerns.
  • Azathioprine – 2 mg/kg/day as an alternative.

Second‑Line / Biologic Therapies

• Tocilizumab (IL‑6 receptor blocker) – case series show improvement in refractory EF.
• Rituximab (anti‑CD20) – used in patients with concurrent autoimmune disease or severe fibrosis.
• Dupilumab – an IL‑4/IL‑13 inhibitor that targets eosinophilic pathways; early reports are promising.

Physical and Occupational Therapy

Therapy is essential from diagnosis onward to preserve range of motion, prevent contractures, and maintain function.

Adjunctive Measures

• Analgesics – acetaminophen or NSAIDs for pain (use cautiously if renal disease present).
• Compression garments – gentle compression may reduce edema and improve skin pliability.
• Vitamin D & Calcium – supplement if long‑term steroids are used to protect bone health.

Living with Eosinophilic Fasciitis

Managing EF is a lifelong partnership between you, your rheumatologist, and allied health professionals.

Daily Management Tips

• Exercise wisely – low‑impact activities (walking, swimming, stationary bike) maintain muscle strength without over‑stretching the fascia.
• Stretching routine – perform gentle, therapist‑prescribed stretches 2–3 times daily to maintain flexibility.
• Skin care – moisturize regularly to prevent cracking; avoid tight clothing that may exacerbate constriction.
• Medication adherence – keep a medication calendar, set reminders, and discuss any side effects promptly.
• Monitor labs – schedule regular CBC, liver function, and bone density tests per your physician’s plan.
• Support network – consider joining an autoimmune‑disease support group (online or local) for shared experiences.

Psychosocial Considerations

Chronic illness can impact mood and work life. Cognitive‑behavioral therapy (CBT), counseling, or a patient‑navigator program can help address anxiety or depression that may accompany physical limitations.

Prevention

Because EF’s exact cause is unclear, primary prevention is challenging. However, the following strategies may lower risk or reduce severity:

• Avoid sudden, excessive physical strain if you have a history of autoimmune disease.
• Discuss with your physician before starting new medications known to trigger immune reactions.
• Maintain a balanced diet rich in omega‑3 fatty acids (fish, flaxseed) that may modulate inflammation.
• Stay up‑to‑date with vaccinations; infections can occasionally act as triggers.

Complications

If left untreated or poorly controlled, EF can lead to serious sequelae:

• Permanent contractures – irreversible joint stiffness and loss of limb function.
• Muscle atrophy due to chronic immobilization.
• Secondary osteoporosis from prolonged corticosteroid use.
• Skin ulceration or secondary infection over hardened areas.
• Rarely, involvement of the visceral fascia (e.g., esophageal) leading to dysphagia.

When to Seek Emergency Care

References

1. Shulman LE, et al. “Eosinophilic fasciitis.” Ann Intern Med. 1995;122(7):518‑523.
2. Mayo Clinic. “Eosinophilic fasciitis.” Updated 2023. https://www.mayoclinic.org
3. Cleveland Clinic. “Eosinophilic Fasciitis (Shulman Disease).” 2022. https://my.clevelandclinic.org
4. NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Eosinophilic Fasciitis Fact Sheet.” 2021.
5. Wang Q, et al. “Biologic therapies in refractory eosinophilic fasciitis: a systematic review.” Rheumatology (Oxford). 2023;62(9):2585‑2594.

```